Brenda W Cooper MD

Oncology•Cleveland, OH

Hematologic Oncology

Professor of Medicine, Case West Res University

Join to View Full Profile

11100 Euclid AveCleveland, OH 44106
Phone+1 216-844-8500

Education & Training

University of MarylandFellowship, Hematology and Medical Oncology, 1987 - 1989
Johns Hopkins University/Bayview Medical CenterResidency, Internal Medicine, 1984 - 1987
Johns Hopkins University School of MedicineClass of 1984

Certifications & Licensure

OH State Medical License 1989 - 2027
MD State Medical License 1986 - 1990
American Board of Internal Medicine Internal Medicine
American Board of Internal Medicine Medical Oncology

Clinical Trials

Combination Chemotherapy in Treating Patients With Recurrent or Refractory Leukemia Start of enrollment: 1994 Aug 01
Completed
Phase 1
Umbilical Cord Blood Transplantation in Treating Patients With High-Risk Hematologic Cancer Start of enrollment: 1998 Jan 01
Completed
Phase 2
Chemotherapy Followed by Surgery in Treating Women With Stage II or Stage III Breast Cancer Start of enrollment: 1999 Feb 01
Completed
Phase 2
Fludarabine, Carboplatin, and Topotecan in Treating Patients With Relapsed/Refractory Acute Leukemia or Advanced Myelodysplastic Syndrome Start of enrollment: 1998 Sep 01
Completed
Phase 1
Adjuvant Stage 2-3A Breast Cancer With Positive Lymph Nodes Start of enrollment: 2000 Jul 01
Completed
Phase 2
Fludarabine/Carboplatin/Topotecan w/Thalidomide for Relapsed/Refractory AML, CML and MDS Start of enrollment: 2002 Sep 01
Completed
Phase 2
Midostaurin and Azacitidine in Treating Elderly Patients With Acute Myelogenous Leukemia Start of enrollment: 2009 Jul 01
Completed
Phase 1, Phase 2
Donor Umbilical Cord Blood Stem Cell Transplant in Treating Patients With Hematologic Malignancies Start of enrollment: 2007 Sep 01
Completed
Phase 2
Double Cord Versus Haploidentical (BMT CTN 1101) Start of enrollment: 2012 Jun 01
Completed
Phase 3
Decitabine, Cytarabine, and Daunorubicin Hydrochloride in Treating Patients With Acute Myeloid Leukemia Start of enrollment: 2011 Sep 16
Active, not recruiting
Phase 2
Cytarabine and Daunorubicin Hydrochloride or Idarubicin and Cytarabine With or Without Vorinostat in Treating Younger Patients With Previously Untreated Acute Myeloid Leukemia Start of enrollment: 2013 Feb 12
Completed
Phase 3
Ixazomib, Mitoxantrone Hydrochloride, Etoposide, and Intermediate-Dose Cytarabine in Relapsed or Refractory Acute Myeloid Leukemia Start of enrollment: 2014 Oct 08
Completed
Phase 1
Gilteritinib vs Midostaurin in FLT3 Mutated Acute Myeloid Leukemia Start of enrollment: 2019 Dec 06
ACTIVE_NOT_RECRUITING
PHASE2
A Study of TAK-981 Given With Rituximab in Adults With Relapsed or Refractory CD20-Positive Non-Hodgkin Lymphoma Start of enrollment: 2019 Oct 15
Terminated
Phase 1, Phase 2
Roles: Principal Investigator
Join now to see all

Publications & Presentations

PubMed

Treatment of non-Hodgkin lymphoma with point-of-care manufactured CAR T cells: a dual institution, phase 1 trial.
Armin Ghobadi, Paolo F Caimi, Jane S Reese, Krishna Goparaju, Martina di Trani
Eclinicalmedicine. 2025-03-01
Melphalan 140 mg/mis Safe and Effective for Frail and Older Multiple Myeloma Patients With Comparable Rates of Minimal Residual Disease Negativity.
Jeries Kort, Nikolas Naleid, Frank Oley, James Ignatz-Hoover, Seunghee Margevicius
Clinical Lymphoma, Myeloma & Leukemia. 2025-02-20
Lenalidomide, rituximab (R), and ixazomib for frontline treatment of high risk follicular and indolent non-Hodgkin lymphoma.
Brian T Hill, Yanwen Chen, Deepa Jagadeesh, Robert Dean, Omer Koc
Leukemia & Lymphoma. 2024-06-01

Abstracts/Posters

Lymphoma-Specific Venous Thromboembolism Score (LyV-Score): Use of Lymphoma Subtype to Refine Risk Prediction
Brenda Cooper, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
Phase 1 Study of on Site Manufactured Anti-CD19 CAR-T Cells: Responses in Subjects with Rapidly Progressive Refractory Lymphomas
Brenda Cooper, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
A Double-Blind, Placebo-Controlled, Phase 3 Registration Trial to Evaluate the Efficacy of Uproleselan (GMI-1271) with Standard Salvage Chemotherapy in Patients with R...
Brenda Cooper, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
Inotuzumab Ozogamicin Post-Transplant for Acute Lymphocytic Leukemia
Brenda Cooper, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
Filgrastim Administered after Early Assessment Bone Marrow Biopsy during 7+3 Induction Therapy for Acute Myeloid Leukemia Reduces Length of Hospital Stay
Brenda Cooper, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
Preclinical Studies and Phase I Trial of Vactosertib in Combination with Pomalidomide in Relapsed Multiple Myeloma: A Corticosteroid-Free Approach By Targeting TGF-_ S...
Brenda Cooper, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
Join now to see all

Grant Support

SB-715992 In Acute LeukemiasNational Center For Research Resources2005–2006
Mechanism Based Phase I Trial Of Topotecan In LeukemiaNational Cancer Institute1999–2000
Sequential Topotecan &Etoposide For Patients With Myeloid LeukemiaNational Center For Research Resources1997–1999